NCT01885598 is a clinical trial of Apixaban in NonValvular Atrial Fibrillation, sponsored by Bristol-Myers Squibb.

Who is sponsoring NCT01885598?

NCT01885598 is sponsored by Bristol-Myers Squibb.

What drugs are being tested in NCT01885598?

Interventions in NCT01885598: Apixaban.

What condition does NCT01885598 study?

NCT01885598 studies NonValvular Atrial Fibrillation.

Is NCT01885598 still recruiting?

NCT01885598 is currently completed. Last updated 31 October 2017.

Last reviewed 2017-10-31 · How we verify

NCT01885598

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eliquis Regulatory Post Marketing Surveillance

Completed Last updated 31 October 2017

What this trial tests

trial testing Apixaban in NonValvular Atrial Fibrillation in 3,335 participants. Completed in 29 September 2017.

Timeline

10 July 2013

Primary endpoint
29 September 2017

29 September 2017

Quick facts

Lead sponsor	Bristol-Myers Squibb
Status	Completed
Study type	OBSERVATIONAL
Enrollment	3,335
Start date	10 July 2013
Primary completion	29 September 2017
Estimated completion	29 September 2017
Sites	1 location across South Korea

Drugs / interventions tested

Apixaban (apixaban) — full drug profile →

Conditions studied

NonValvular Atrial Fibrillation — all drugs for NonValvular Atrial Fibrillation →

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

19 and older, any sex, with NonValvular Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to examine the safety profile of Eliquis in Korean nonvalvular atrial fibrillation patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Apixaban for Secondary Stroke Prevention: Coexistant Cerebral Atherosclerosis May Increase Recurrent Strokes.
Kim JS, Koo J, Shin DI, Kim BS, et al · · 2022 · cited 6× · PMID 35135065 · DOI 10.5853/jos.2021.02355

Verify or expand the search:

Other trials of Apixaban

Trials testing the same drug.

NCT06953726 — Comparing the Safety and Efficacy of Apixaban and Rivaroxaban · Phase 4 · not yet recruiting
NCT07493304 — Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Canc · Phase 3 · not yet recruiting
NCT07521332 — Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis · Phase 4 · recruiting
NCT07160686 — Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment · Phase 3 · not yet recruiting
NCT07404345 — Low-Dose Apixaban Added to Standard Heparin Lock Versus Heparin Lock Alone to Prevent Tunneled Hemodialysis Catheters Dy · Phase 4 · not yet recruiting

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01885598 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
Last refreshed: 31 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01885598.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing